Patients were stratified by breast cancer subtype: human epidermal growth factor receptor 2 positive/hormone receptor positive (HER2+/HR+), HER2+/hormone receptor negative (HER2+/HR-), HR+/HER2-, and triple-negative breast cancer (TNBC). Here, ERBB2 is linked to breast cancer.